Get the Stockscreener App
0.00
100.00%
-3.875
Virios Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia ("FM") and Long-COVID ("LC"). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
See More
Previous Close:
$3.875
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$4.30M
Revenue:
-
Net Income/Loss:
$-5.30M
P/E Ratio:
0.00
EPS:
-0.55
Net Cash Flow:
$-4.87M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$26.00
Virios Therapeutics Inc Stock (VIRI) Company Profile
Name
Virios Therapeutics Inc
Sector
Industry
Phone
(866) 620-8655
Address
44 MILTON AVENUE, ALPHARETTA
Virios Therapeutics Inc Stock (VIRI) Latest News
Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 - Marketscreener.com
Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023 - Marketscreener.com
Dogwood Therapeutics to Report Third Quarter 2024 Financial - GlobeNewswire
Dogwood Therapeutics regains Nasdaq compliance - Investing.com
Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
DWTXDogwood Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Virios Therapeutics (VIRI) Price Target Increased by 14.29% to 4.08 - MSN
Virios Therapeutics’ Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid Fibromyalgia - Marketscreener.com
Dogwood Therapeutics : Corporate Presentation (Virios DWTX Inc. Corporate Overview Q4 2024) - Marketscreener.com
Dogwood Therapeutics, Inc. Expected to Earn Q3 2024 Earnings of ($1.40) Per Share (NASDAQ:DWTX) - Defense World
Dogwood Therapeutics, Inc.DWTX: Virios Therapeutics Becomes Dogwood Therapeutics - Smartkarma
VIRIOS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 - Marketscreener.com
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study - Marketscreener.com
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 - Marketscreener.com
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update - Marketscreener.com
Virios Therapeutics shares target raised on Wex merger news By Investing.com - Investing.com South Africa
Virios Therapeutics shares target raised on Wex merger news - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, NAPA, VIRI on Behalf of Shareholders - ForexTV.com
Virios Therapeutics Transforms into Dogwood Therapeutics - Yahoo Finance
Financial Metrics Unveiled: Virios Therapeutics Inc (VIRI)’s Key Ratios in the Spotlight - The Dwinnex
CKLIFE SCIENCES Hopes to Introduce Investors for Newly Merged Dogwood (DWTX.US) - AASTOCKS.com
Virios Therapeutics announces strategic merger and financing - Investing.com
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. to Combine to Form Dogwood Therapeutics, Inc. - Orrick
Virios Therapeutics Inc (VIRI) Stock: A Year of Decreases and Increases - The InvestChronicle
Virios Therapeutics Inc (NASDAQ: VIRI)’s Stock Reduces -19.21%, Making It A Good Investment - Stocks Register
Predicting Virios Therapeutics Inc’s (VIRI) earnings for the current quarter - US Post News
Virios Therapeutics And Wex Pharmaceuticals To Merge - citybiz
VIRI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Virios Therapeutics, Inc. Is Fair to Shareholders - The Bakersfield Californian
Virios Therapeutics, Wex Pharmaceuticals announce business combination agreement - TipRanks
Virios, and Wex Pharmaceuticals report business combination to form Dogwood Therapeutics - MSN
Virios Therapeutics, Inc. Announces Management Changes - Marketscreener.com
Virios Therapeutics announces strategic merger and financing By Investing.com - Investing.com Australia
Conjoint Inc. Enters into the Loan Agreement with the Virios Therapeutics, Inc - Marketscreener.com
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. - GlobeNewswire
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) - Yahoo Finance
Virios Therapeutics, Inc. acquired Pharmagesic Inc. from Sealbond Limited. - Marketscreener.com
Investing in Virios Therapeutics Inc (VIRI) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid - Marketscreener.com
Virios Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Virios Therapeutics Inc (VIRI) Stock: A Year of Market Fluctuations - The InvestChronicle
Daily Progress: Virios Therapeutics Inc (VIRI) Drop -9.09, Closing at 0.17 - The Dwinnex
Virios Therapeutics stock hits 52-week low at $0.15 - Investing.com
Virios Therapeutics (NASDAQ:VIRI) Stock Quotes, Forecast and News Summary - Benzinga
The Psychology of Virios Therapeutics Inc Inc. (VIRI) Price Performance: Understanding Market Sentiment - The InvestChronicle
It would be worthwhile to take a closer look at Virios Therapeutics Inc (VIRI) - US Post News
Vicor Corporation Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationVICR - AccessWire
MONDAY INVESTOR DEADLINE: Vicor Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitVICR - AccessWire
Virios Therapeutics Inc (VIRI) Stock: From Low to High in 52 Weeks - The InvestChronicle
Virios Therapeutics Inc (VIRI)’s Market Momentum: Closing Strong at 0.19, Up 7.78 - The Dwinnex
Take off with Virios Therapeutics Inc (VIRI): Get ready for trading - SETE News
Virios Therapeutics Inc Stock (VIRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):